Show simple item record

dc.contributor.authorLiu, Guozheng
dc.contributor.authorHnatowich, Donald J.
dc.date2022-08-11T08:09:32.000
dc.date.accessioned2022-08-23T16:34:35Z
dc.date.available2022-08-23T16:34:35Z
dc.date.issued2007-05-17
dc.date.submitted2009-03-16
dc.identifier.citationAnticancer Agents Med Chem. 2007 May;7(3):367-77.
dc.identifier.issn1871-5206 (Print)
dc.identifier.pmid17504162
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38369
dc.description.abstractFor radiotherapy, biomolecules such as intact antibodies, antibody fragments, peptides, DNAs and other oligomers have all been labeled with radiorhenium ((186)Re and (188)Re). Three different approaches have been employed that may be referred to as direct, indirect and integral labeling. Direct labeling applies to proteins and involves the initial reduction of endogenous disulfide bridges to provide chelation sites. Indirect labeling can apply to most biomolecules and involves the initial attachment of an exogenous chelator. Finally, integral labeling is a special case applying only to small molecules in which the metallic radionuclide serves to link two parts of a biomolecule together in forming the labeled complex. While the number of varieties for the direct and integral radiolabeling approaches is rather limited, a fairly large and diverse number of chelators have been reported in the case of indirect labeling. Our objective herein is to provide an overview of the various chelators that have been used in the indirect labeling of biomolecules with radiorhenium, including details on the labeling procedures, the stability of the radiolabel and, where possible, the influence of the label on biological properties.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17504162&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1949414/?tool=pubmed
dc.subjectAnimals
dc.subjectChelating Agents
dc.subjectHumans
dc.subjectHydrazines
dc.subjectHydroxamic Acids
dc.subjectNicotinic Acids
dc.subjectPhosphines
dc.subjectRadioisotopes
dc.subjectRadiopharmaceuticals
dc.subjectRhenium
dc.subjectSuccinates
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleLabeling biomolecules with radiorhenium: a review of the bifunctional chelators
dc.typeJournal Article
dc.source.journaltitleAnti-cancer agents in medicinal chemistry
dc.source.volume7
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1232
dc.identifier.contextkey782898
html.description.abstract<p>For radiotherapy, biomolecules such as intact antibodies, antibody fragments, peptides, DNAs and other oligomers have all been labeled with radiorhenium ((186)Re and (188)Re). Three different approaches have been employed that may be referred to as direct, indirect and integral labeling. Direct labeling applies to proteins and involves the initial reduction of endogenous disulfide bridges to provide chelation sites. Indirect labeling can apply to most biomolecules and involves the initial attachment of an exogenous chelator. Finally, integral labeling is a special case applying only to small molecules in which the metallic radionuclide serves to link two parts of a biomolecule together in forming the labeled complex. While the number of varieties for the direct and integral radiolabeling approaches is rather limited, a fairly large and diverse number of chelators have been reported in the case of indirect labeling. Our objective herein is to provide an overview of the various chelators that have been used in the indirect labeling of biomolecules with radiorhenium, including details on the labeling procedures, the stability of the radiolabel and, where possible, the influence of the label on biological properties.</p>
dc.identifier.submissionpathoapubs/1232
dc.contributor.departmentDepartment of Radiology, Division of Nuclear Medicine
dc.source.pages367-77


This item appears in the following Collection(s)

Show simple item record